Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium

Bruce Kaplan, Herwig Ulf Meier-Kriesche, Paula Minnick, Marie Claude Bastien, Romain Sechaud, Ching Ming Yeh, Sebastien Balez, Franck Picard, Robert Schmouder

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Enteric-coated mycophenolate sodium (EC-MPS) (myfortic®) is an advanced formulation delivering mycophenolic acid (MPA), designed to improve MPA-related upper gastrointestinal adverse events by delaying the release of MPA until the small intestine. A randomized, calcineurin inhibitor crossover, steady-state pharmacokinetic study in stable renal transplant patients receiving EC-MPS demonstrated increased MPA exposure of 19% higher, MPA Cmax,ss 19% lower and MPA Cmin,ss approximately twofold higher with tacrolimus, than cyclosporine microemulsion. No study drug-related adverse events were recorded, but mean blood glucose concentration was higher in patients receiving tacrolimus (p = 0.031). The dose changes in relation to MPA exposure in patients is dependent on the clinical situation and may not always be warranted. These observations should be taken into consideration when switching from one calcineurin inhibitor to another, but the final dosage should be based on both this pharmacokinetic data and the clinical situation.

Original languageEnglish (US)
Pages (from-to)551-558
Number of pages8
JournalClinical Transplantation
Volume19
Issue number4
DOIs
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

Mycophenolic Acid
Cross-Over Studies
Pharmacokinetics
Tacrolimus
Calcineurin Inhibitors
Drug-Related Side Effects and Adverse Reactions
Cyclosporine
Small Intestine
Blood Glucose

Keywords

  • Calcineurin inhibitors
  • Cyclosporine microemulsion
  • Enteric-coated mycophenolate sodium
  • Myfortic®
  • Pharmacokinetics
  • Tacrolimus

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. / Kaplan, Bruce; Meier-Kriesche, Herwig Ulf; Minnick, Paula; Bastien, Marie Claude; Sechaud, Romain; Yeh, Ching Ming; Balez, Sebastien; Picard, Franck; Schmouder, Robert.

In: Clinical Transplantation, Vol. 19, No. 4, 08.2005, p. 551-558.

Research output: Contribution to journalArticle

Kaplan, B, Meier-Kriesche, HU, Minnick, P, Bastien, MC, Sechaud, R, Yeh, CM, Balez, S, Picard, F & Schmouder, R 2005, 'Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium', Clinical Transplantation, vol. 19, no. 4, pp. 551-558. https://doi.org/10.1111/j.1399-0012.2005.00387.x
Kaplan, Bruce ; Meier-Kriesche, Herwig Ulf ; Minnick, Paula ; Bastien, Marie Claude ; Sechaud, Romain ; Yeh, Ching Ming ; Balez, Sebastien ; Picard, Franck ; Schmouder, Robert. / Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. In: Clinical Transplantation. 2005 ; Vol. 19, No. 4. pp. 551-558.
@article{67fe5d7723c442d89371641f546052bd,
title = "Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium",
abstract = "Enteric-coated mycophenolate sodium (EC-MPS) (myfortic{\circledR}) is an advanced formulation delivering mycophenolic acid (MPA), designed to improve MPA-related upper gastrointestinal adverse events by delaying the release of MPA until the small intestine. A randomized, calcineurin inhibitor crossover, steady-state pharmacokinetic study in stable renal transplant patients receiving EC-MPS demonstrated increased MPA exposure of 19{\%} higher, MPA Cmax,ss 19{\%} lower and MPA Cmin,ss approximately twofold higher with tacrolimus, than cyclosporine microemulsion. No study drug-related adverse events were recorded, but mean blood glucose concentration was higher in patients receiving tacrolimus (p = 0.031). The dose changes in relation to MPA exposure in patients is dependent on the clinical situation and may not always be warranted. These observations should be taken into consideration when switching from one calcineurin inhibitor to another, but the final dosage should be based on both this pharmacokinetic data and the clinical situation.",
keywords = "Calcineurin inhibitors, Cyclosporine microemulsion, Enteric-coated mycophenolate sodium, Myfortic{\circledR}, Pharmacokinetics, Tacrolimus",
author = "Bruce Kaplan and Meier-Kriesche, {Herwig Ulf} and Paula Minnick and Bastien, {Marie Claude} and Romain Sechaud and Yeh, {Ching Ming} and Sebastien Balez and Franck Picard and Robert Schmouder",
year = "2005",
month = "8",
doi = "10.1111/j.1399-0012.2005.00387.x",
language = "English (US)",
volume = "19",
pages = "551--558",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium

AU - Kaplan, Bruce

AU - Meier-Kriesche, Herwig Ulf

AU - Minnick, Paula

AU - Bastien, Marie Claude

AU - Sechaud, Romain

AU - Yeh, Ching Ming

AU - Balez, Sebastien

AU - Picard, Franck

AU - Schmouder, Robert

PY - 2005/8

Y1 - 2005/8

N2 - Enteric-coated mycophenolate sodium (EC-MPS) (myfortic®) is an advanced formulation delivering mycophenolic acid (MPA), designed to improve MPA-related upper gastrointestinal adverse events by delaying the release of MPA until the small intestine. A randomized, calcineurin inhibitor crossover, steady-state pharmacokinetic study in stable renal transplant patients receiving EC-MPS demonstrated increased MPA exposure of 19% higher, MPA Cmax,ss 19% lower and MPA Cmin,ss approximately twofold higher with tacrolimus, than cyclosporine microemulsion. No study drug-related adverse events were recorded, but mean blood glucose concentration was higher in patients receiving tacrolimus (p = 0.031). The dose changes in relation to MPA exposure in patients is dependent on the clinical situation and may not always be warranted. These observations should be taken into consideration when switching from one calcineurin inhibitor to another, but the final dosage should be based on both this pharmacokinetic data and the clinical situation.

AB - Enteric-coated mycophenolate sodium (EC-MPS) (myfortic®) is an advanced formulation delivering mycophenolic acid (MPA), designed to improve MPA-related upper gastrointestinal adverse events by delaying the release of MPA until the small intestine. A randomized, calcineurin inhibitor crossover, steady-state pharmacokinetic study in stable renal transplant patients receiving EC-MPS demonstrated increased MPA exposure of 19% higher, MPA Cmax,ss 19% lower and MPA Cmin,ss approximately twofold higher with tacrolimus, than cyclosporine microemulsion. No study drug-related adverse events were recorded, but mean blood glucose concentration was higher in patients receiving tacrolimus (p = 0.031). The dose changes in relation to MPA exposure in patients is dependent on the clinical situation and may not always be warranted. These observations should be taken into consideration when switching from one calcineurin inhibitor to another, but the final dosage should be based on both this pharmacokinetic data and the clinical situation.

KW - Calcineurin inhibitors

KW - Cyclosporine microemulsion

KW - Enteric-coated mycophenolate sodium

KW - Myfortic®

KW - Pharmacokinetics

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=22244431879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22244431879&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2005.00387.x

DO - 10.1111/j.1399-0012.2005.00387.x

M3 - Article

C2 - 16008604

AN - SCOPUS:22244431879

VL - 19

SP - 551

EP - 558

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 4

ER -